TScan Therapeutics (NASDAQ:TCRX) Receives "Outperform" Rating from Wedbush

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "outperform" rating reiterated by Wedbush in a research report issued to clients and investors on Tuesday,RTT News reports. They currently have a $7.00 price target on the stock. Wedbush's price objective would suggest a potential upside of 444.75% from the stock's previous close. Wedbush also issued estimates for TScan Therapeutics' Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at ($0.99) EPS, FY2028 earnings at ($0.92) EPS and FY2029 earnings at ($0.91) EPS.

Several other equities research analysts also recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 6th. Needham & Company LLC reissued a "buy" rating and set a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Barclays cut their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $10.00 price target on shares of TScan Therapeutics in a report on Friday, March 14th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $8.50.

TScan Therapeutics Price Performance

TCRX stock traded down $0.10 during trading on Tuesday, reaching $1.29. 244,572 shares of the company were exchanged, compared to its average volume of 362,468. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The company has a market capitalization of $72.72 million, a price-to-earnings ratio of -1.21 and a beta of 1.06. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $9.69. The company has a 50-day moving average of $1.49 and a two-hundred day moving average of $2.70.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.62 million. As a group, equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. purchased a new position in shares of TScan Therapeutics during the fourth quarter worth approximately $32,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of TScan Therapeutics during the fourth quarter worth $32,000. ProShare Advisors LLC acquired a new stake in TScan Therapeutics in the fourth quarter worth about $40,000. Wells Fargo & Company MN grew its position in TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after purchasing an additional 5,694 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of TScan Therapeutics in the 4th quarter valued at $59,000. Institutional investors own 82.83% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.